Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Navis

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Journal of Human Hypertension|October 1, 1996
Titrating for antiproteinuric effect: the clue to renoprotection?G Navis, D de Zeeuw
The Netherlands Journal of Medicine|January 7, 2011
Time for a comeback of NSAIDs in proteinuric chronic kidney disease?L Vogt, G D Laverman, G Navis
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 29, 1998
Norepinephrine-induced blood pressure rise and renal vasoconstriction are not attenuated by enalapril treatment in microalbuminuric IDDMK Hoogenberg, G Navis, R P Dullaart
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 27, 2017
Hyperfiltration After Donation and Living Kidney Donor RiskM van Londen, J van der Weijden, G Navis
Lancet (London, England)|June 28, 1997
ACE-inhibitors: panacea for progressive renal diseaseG Navis, D de Zeeuw, P E de Jong
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 1, 1997
I/D polymorphism of the angiotensin converting enzyme gene: a clue to the heterogeneity in the progression of renal disease and in the renal response to therapy?G Navis, P E de Jong, D de Zeeuw
Advances in Nephrology From the Necker Hospital|January 1, 1997
Optimizing the renal response to ace inhibition: a strategy toward more effective long-term renoprotectionG Navis, P E de Jong, D de Zeeuw
Lancet (London, England)|August 7, 1999
Renoprotective therapy: titration against urinary protein excretionP E De Jong, G Navis, D de Zeeuw
Diabetologia|August 20, 2009
Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetesS J L Bakker, G Navis, R O B Gans
The Journal of Pathology|March 15, 2006
ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy ratsI Hamming, G Navis, M J A Kocks, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Journal of Human Hypertension|October 1, 1996
Titrating for antiproteinuric effect: the clue to renoprotection?G Navis, D de Zeeuw
The Netherlands Journal of Medicine|January 7, 2011
Time for a comeback of NSAIDs in proteinuric chronic kidney disease?L Vogt, G D Laverman, G Navis
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 29, 1998
Norepinephrine-induced blood pressure rise and renal vasoconstriction are not attenuated by enalapril treatment in microalbuminuric IDDMK Hoogenberg, G Navis, R P Dullaart
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 27, 2017
Hyperfiltration After Donation and Living Kidney Donor RiskM van Londen, J van der Weijden, G Navis
Lancet (London, England)|June 28, 1997
ACE-inhibitors: panacea for progressive renal diseaseG Navis, D de Zeeuw, P E de Jong
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 1, 1997
I/D polymorphism of the angiotensin converting enzyme gene: a clue to the heterogeneity in the progression of renal disease and in the renal response to therapy?G Navis, P E de Jong, D de Zeeuw
Advances in Nephrology From the Necker Hospital|January 1, 1997
Optimizing the renal response to ace inhibition: a strategy toward more effective long-term renoprotectionG Navis, P E de Jong, D de Zeeuw
Lancet (London, England)|August 7, 1999
Renoprotective therapy: titration against urinary protein excretionP E De Jong, G Navis, D de Zeeuw
Diabetologia|August 20, 2009
Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetesS J L Bakker, G Navis, R O B Gans
The Journal of Pathology|March 15, 2006
ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy ratsI Hamming, G Navis, M J A Kocks, et al.
Pageof 7